138 related articles for article (PubMed ID: 3051071)
1. Tyramine sulfate excretion may be a better predictor of antidepressant response than monoamine oxidase activity.
Stewart JW; Harrison W; Cooper TB; Quitkin FM
Psychiatry Res; 1988 Aug; 25(2):195-201. PubMed ID: 3051071
[TBL] [Abstract][Full Text] [Related]
2. Phenelzine v imipramine in atypical depression. A preliminary report.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF
Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621
[TBL] [Abstract][Full Text] [Related]
3. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design.
Quitkin FM; Harrison W; Stewart JW; McGrath PJ; Tricamo E; Ocepek-Welikson K; Rabkin JG; Wager SG; Nunes E; Klein DF
Arch Gen Psychiatry; 1991 Apr; 48(4):319-23. PubMed ID: 2009033
[TBL] [Abstract][Full Text] [Related]
4. A comparison of phenelzine and imipramine in depressed inpatients.
Davidson JR; McLeod MN; Turnbull CD; Miller RD
J Clin Psychiatry; 1981 Oct; 42(10):395-7. PubMed ID: 7026542
[TBL] [Abstract][Full Text] [Related]
5. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.
Raft D; Davidson J; Wasik J; Mattox A
Neuropsychobiology; 1981; 7(3):122-6. PubMed ID: 7231652
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant specificity in atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
[TBL] [Abstract][Full Text] [Related]
7. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.
McGrath PJ; Stewart JW; Nunes EV; Ocepek-Welikson K; Rabkin JG; Quitkin FM; Klein DF
Am J Psychiatry; 1993 Jan; 150(1):118-23. PubMed ID: 8417553
[TBL] [Abstract][Full Text] [Related]
8. MAO inhibition and clinical response in depressed patients treated with phenelzine.
Bresnahan DB; Pandey GN; Janicak PG; Sharma R; Boshes RA; Chang SS; Gierl BL; Davis JM
J Clin Psychiatry; 1990 Feb; 51(2):47-50. PubMed ID: 2298705
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine.
Georgotas A; McCue RE; Cooper TB; Nagachandran N; Friedhoff A
Psychiatry Res; 1989 Apr; 28(1):1-9. PubMed ID: 2662234
[TBL] [Abstract][Full Text] [Related]
10. Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment.
Stewart JW; Quitkin FM; McGrath PJ; Rabkin JG; Markowitz JS; Tricamo E; Klein DF
Psychiatry Res; 1988 Aug; 25(2):213-22. PubMed ID: 3051072
[TBL] [Abstract][Full Text] [Related]
11. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.
Stewart JW; McGrath PJ; Quitkin FM; Harrison W; Markowitz J; Wager S; Leibowitz MR
Arch Gen Psychiatry; 1989 Dec; 46(12):1080-7. PubMed ID: 2686575
[TBL] [Abstract][Full Text] [Related]
12. Chronic depression: response to placebo, imipramine, and phenelzine.
Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E
J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152
[TBL] [Abstract][Full Text] [Related]
13. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG
Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631
[TBL] [Abstract][Full Text] [Related]
14. Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study.
Walsh BT; Stewart JW; Roose SP; Gladis M; Glassman AH
Arch Gen Psychiatry; 1984 Nov; 41(11):1105-9. PubMed ID: 6388524
[TBL] [Abstract][Full Text] [Related]
15. An outpatient evaluation of phenelzine and imipramine.
Davidson J; Raft D; Pelton S
J Clin Psychiatry; 1987 Apr; 48(4):143-6. PubMed ID: 3549705
[TBL] [Abstract][Full Text] [Related]
16. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine.
Rabkin JG; Markowitz JS; Stewart J; McGrath P; Harrison W; Quitkin FM; Klein DF
Psychiatry Res; 1986 Sep; 19(1):75-86. PubMed ID: 3538107
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment dexamethasone suppression test as a predictor of response to phenelzine.
Janicak PG; Pandey GN; Sharma R; Boshes R; Bresnahan D; Davis JM
J Clin Psychiatry; 1987 Dec; 48(12):480-2. PubMed ID: 3693333
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to nortriptyline and phenelzine by platelet MAO activity.
Georgotas A; McCue RE; Friedman E; Cooper T
Am J Psychiatry; 1987 Mar; 144(3):338-40. PubMed ID: 3826434
[TBL] [Abstract][Full Text] [Related]
19. Double-blind study of imipramine versus phenelzine in Melancholias and Dysthymic Disorders.
Vallejo J; Gasto C; Catalan R; Salamero M
Br J Psychiatry; 1987 Nov; 151():639-42. PubMed ID: 3446308
[TBL] [Abstract][Full Text] [Related]
20. Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine.
Sharma RP; Janicak PG; Javaid JI; Pandey GN; Gierl B; Davis JM
Am J Psychiatry; 1990 Oct; 147(10):1318-21. PubMed ID: 2169208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
